RxDoctor Payments Data

Cindy Hernandez, DO

Ophthalmology · Coral Springs, FLNPI 1407977978

Payments from drug & device makers

$6,580in general payments, 2019–2025

Across 236 payments — averaging $27.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Biohaven Pharmaceuticals, Inc.$586
  • EMD Serono, Inc.$508
  • UCB, Inc.$417
  • AbbVie$389
  • Eisai Inc.$372
  • plus $3K from 33 others

What the payments were for

  • Speaking & faculty fees$210%
  • Travel & lodging$1,30120%
  • Food & beverage$5,25780%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,580 in reported general payments places this provider in the 75th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$51,814
Medicare patients
124
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod51$26,959
RestasisCyclosporine33$19,121
Prednisolone Acetate90$5,732
CombiganBrimonidine Tartrate/Timolol12$5,297
IlevroNepafenac11$4,204
Ketorolac Tromethamine57$3,329
MoxifloxacinMoxifloxacin Hcl45$1,766
Tobramycin-DexamethasoneTobramycin/Dexamethasone21$1,531
Latanoprost172$1,367
Cyclosporine12$985
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$495
ErythromycinErythromycin Base47$470
Dorzolamide Hcl21$364
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha17$174
Timolol Maleate18$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$15$26,95951 claims
AbbVieRestasis, Combigan$389$24,41745 claims
NovartisIlevro$18$4,20411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Coral Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →